Infinity Pharmaceuti (INFI) 4.81 $INFI
Infinity Announces Launch Of Disease Awareness Campaign For Hematologic Malignancies
PR Newswire - Wed Jun 01, 7:05AM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the launch of a mechanism of disease (MOD) awareness initiative designed to educate community and academic hematologists/oncologists about the role of the tumor microenvironment in patients with certain hematologic malignancies, or blood cancers. With more research emerging about the role of the tumor microenvironment in hematologic malignancies, Infinity developed this campaign to contribute to the emerging knowledge of this scientific concept and its clinical relevance. The initiative will be showcased in the Infinity booth (#22415) at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from June 3 - June 7, 2016. Additional information and resources on the tumor microenvironment are available on a newly launched website: www.manipulatedTME.com.
INFI: 4.81 (-0.23)
Infinity To Participate In Three June Investor Conferences
PR Newswire - Tue May 31, 3:05PM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that management will present at the following investor conferences:
INFI: 4.81 (-0.23)
Are These Biotech Stocks Prescribed for Investors' Portfolio? - Anacor Pharma, Athersys, Aralez Pharma and Infinity Pharma
PR Newswire - Fri May 20, 7:10AM CDT
The Biotech arena remains under immense pressure, yet many veteran investors believe that the industry is not far from recovering. There are great companies in this space, and today ActiveWallSt.com featured the following four equities: Anacor Pharmaceuticals Inc. (NASDAQ: ANAC), Athersys Inc. (NASDAQ: ATHX), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Sign up for your free trading alerts on these biotech stocks at:
INFI: 4.81 (-0.23), ARLZ: 3.58 (-0.13), ANAC: 99.17 (+0.09), ATHX: 2.38 (+0.03)
Infinity Announces Presentations On Investigational Development Candidates, Duvelisib And IPI-549, At Upcoming EHA And ASCO Meetings
PR Newswire - Thu May 19, 7:00AM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that new data will be presented for duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, at the 21st Congress of the European Hematology Association (EHA) taking place from June 9 - 12, 2016, in Copenhagen. At the meeting, preliminary data from CONTEMPO, a Phase 1b/2 study evaluating duvelisib in combination with rituximab or obinutuzmab in treatment-naïve follicular lymphoma patients, will be presented in a poster session. Duvelisib is the only dual inhibitor of PI3K-delta,gamma in Phase 3 clinical development and is in registration-focused studies in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) and relapsed/refractory chronic lymphocytic leukemia (CLL). Infinity and AbbVie are jointly developing duvelisib in oncology.
INFI: 4.81 (-0.23)
Infinity Provides Company Update And Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 3:05PM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its first quarter 2016 financial results and ongoing progress with its pipeline, including duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, and IPI-549, an immuno-oncology development candidate that selectively inhibits PI3K-gamma.
INFI: 4.81 (-0.23)
Infinity to Participate in Three May Investor Conferences
PR Newswire - Wed Apr 27, 7:00AM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that management will be participating at the following investor conferences:
DB: 15.74 (-0.97), INFI: 4.81 (-0.23)
Infinity Announces the Date of its First Quarter 2016 Financial Results Conference Call and Webcast
PR Newswire - Wed Apr 20, 7:00AM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Wednesday, May 4, 2016, at 4:30 p.m. ET. During the call, management will review the company's first quarter 2016 financial results and provide an update on Infinity's business.
INFI: 4.81 (-0.23)
IPI-549 Alters the Immune-Suppressive Microenvironment and Enhances the Activity of Checkpoint Inhibitors in Preclinical Models
PR Newswire - Mon Apr 18, 7:00AM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced new preclinical data for IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma). Preclinical data in multiple solid tumor models demonstrate that IPI-549 targets immune cells and alters the immune-suppressive microenvironment, promoting an anti-tumor immune response that leads to tumor growth inhibition. Data also demonstrate that IPI-549 enhances the effects of checkpoint inhibitors, resulting in improved survival in murine models. These data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans, Louisiana. A Phase 1 clinical study is under way to explore the safety and activity of IPI-549 both as a monotherapy and in combination with anti-PD-1 antibody therapy, a type of checkpoint inhibitor.
INFI: 4.81 (-0.23)
Downgrade Alert for Infinity Pharmaceuticals (INFI)
Comtex SmarTrend(R) - Wed Mar 23, 3:29AM CDT
Infinity Pharmaceuticals (NASDAQ:INFI) was downgraded from Neutral to Underperform at Wedbush today. The stock closed yesterday at $5.62 on volume of 1.7 million shares, above average daily volume of 665,000. Over the past year, Infinity Pharmaceuticals has traded in a range of $5.17 to $50.51 and closed yesterday at $5.62, 9% above that low. Over the last five market days, the 200-day moving average (MA) has gone down 1.1% while the 50-day MA has declined 0.5%.
INFI: 4.81 (-0.23)
Downtrend Call Working As Infinity Pharmaceuticals Stock Falls 23.1% (INFI)
Comtex SmarTrend(R) - Fri Mar 04, 4:49PM CST
SmarTrend identified a Downtrend for Infinity Pharmaceuticals (NASDAQ:INFI) on November 11th, 2015 at $8.79. In approximately 4 months, Infinity Pharmaceuticals has returned 23.05% as of today's recent price of $6.76.
INFI: 4.81 (-0.23)
Infinity Pharmaceuticals Down 25.8% Since SmarTrend Downtrend Call (INFI)
Comtex SmarTrend(R) - Fri Mar 04, 1:30PM CST
SmarTrend identified a Downtrend for Infinity Pharmaceuticals (NASDAQ:INFI) on November 11th, 2015 at $8.79. In approximately 4 months, Infinity Pharmaceuticals has returned 25.78% as of today's recent price of $6.52.
INFI: 4.81 (-0.23)
Shares of INFI Down 33.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 19, 9:32AM CST
SmarTrend identified a Downtrend for Infinity Pharmaceuticals (NASDAQ:INFI) on November 11th, 2015 at $8.79. In approximately 3 months, Infinity Pharmaceuticals has returned 32.95% as of today's recent price of $5.89.
INFI: 4.81 (-0.23)
Can DENTSPLY (XRAY) Pull a Surprise this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 12:45PM CST
DENTSPLY International, Inc. (XRAY) is set to report fourth-quarter 2015 earnings results on Feb 12.
AHS: 39.97 (-1.01), INFI: 4.81 (-0.23), XRAY: 63.61 (-0.82), MGLN: 66.77 (-0.65)
NCCN Awarded $2 Million in Research Funding From Infinity Pharmaceuticals to Study Duvelisib in Hematologic Malignancies
Marketwired - Tue Feb 09, 8:05AM CST
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2-million grant from Infinity Pharmaceuticals, Inc. to evaluate the safety and effectiveness of duvelisib as a potential treatment for hematologic malignancies.
INFI: 4.81 (-0.23)
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfgg5w/relapsed_chronic) has announced the addition of the "Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsed Chronic Lymphocytic Leukemia (CLL) Overview - Therapeutics Development - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cyclacel Pharmaceuticals, Inc. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Hutchison MediPharma Limited - ImmunoGen, Inc. - Immunomedics, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Innate Pharma SA - Juno Therapeutics Inc. - Karyopharm Therapeutics, Inc. - Les Laboratoires Servier SAS - LFB S.A. - Lymphocyte Activation Technologies, S.A. - MedImmune, LLC - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Ono Pharmaceutical Co., Ltd. - Portola Pharmaceuticals, Inc. - Sanofi - TG Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/rf...ed_chronic
CYCC: 5.95 (-0.14), ABBV: 61.00 (+0.25), INFI: 4.81 (-0.23), JUNO: 42.98 (-2.55), IMMU: 3.05 (-0.08), PTLA: 26.38 (-0.46), EBS: 42.30 (-1.19), INCY: 80.41 (-1.20), IMGN: 4.96 (-0.11), TGTX: 7.16 (-0.23), BMY: 72.65 (-0.08), GILD: 84.45 (-1.32), AZN: 27.97 (-0.99), CELGZ: 1.46 (-0.04), KPTI: 8.53 (-0.60), NVS: 78.94 (-1.57)
Commit To Buy Infinity Pharmaceuticals At $5, Earn 22.4% Annualized Using Options
StockOptionsChannel.com - Wed Feb 03, 10:52AM CST
Investors eyeing a purchase of Infinity Pharmaceuticals Inc stock, but cautious about paying the going market price of $5.80/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
INFI: 4.81 (-0.23)
Infinity Announces Launch Of Disease Awareness Campaign For Hematologic Malignancies
PR Newswire - Wed Jun 01, 7:05AM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced the launch of a mechanism of disease (MOD) awareness initiative designed to educate community and academic hematologists/oncologists about the role of the tumor microenvironment in patients with certain hematologic malignancies, or blood cancers. With more research emerging about the role of the tumor microenvironment in hematologic malignancies, Infinity developed this campaign to contribute to the emerging knowledge of this scientific concept and its clinical relevance. The initiative will be showcased in the Infinity booth (#22415) at the American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago from June 3 - June 7, 2016. Additional information and resources on the tumor microenvironment are available on a newly launched website: www.manipulatedTME.com.
INFI: 4.81 (-0.23)
Infinity To Participate In Three June Investor Conferences
PR Newswire - Tue May 31, 3:05PM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that management will present at the following investor conferences:
INFI: 4.81 (-0.23)
Are These Biotech Stocks Prescribed for Investors' Portfolio? - Anacor Pharma, Athersys, Aralez Pharma and Infinity Pharma
PR Newswire - Fri May 20, 7:10AM CDT
The Biotech arena remains under immense pressure, yet many veteran investors believe that the industry is not far from recovering. There are great companies in this space, and today ActiveWallSt.com featured the following four equities: Anacor Pharmaceuticals Inc. (NASDAQ: ANAC), Athersys Inc. (NASDAQ: ATHX), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Sign up for your free trading alerts on these biotech stocks at:
INFI: 4.81 (-0.23), ARLZ: 3.58 (-0.13), ANAC: 99.17 (+0.09), ATHX: 2.38 (+0.03)
Infinity Announces Presentations On Investigational Development Candidates, Duvelisib And IPI-549, At Upcoming EHA And ASCO Meetings
PR Newswire - Thu May 19, 7:00AM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that new data will be presented for duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, at the 21st Congress of the European Hematology Association (EHA) taking place from June 9 - 12, 2016, in Copenhagen. At the meeting, preliminary data from CONTEMPO, a Phase 1b/2 study evaluating duvelisib in combination with rituximab or obinutuzmab in treatment-naïve follicular lymphoma patients, will be presented in a poster session. Duvelisib is the only dual inhibitor of PI3K-delta,gamma in Phase 3 clinical development and is in registration-focused studies in patients with relapsed/refractory indolent non-Hodgkin lymphoma (iNHL) and relapsed/refractory chronic lymphocytic leukemia (CLL). Infinity and AbbVie are jointly developing duvelisib in oncology.
INFI: 4.81 (-0.23)
Infinity Provides Company Update And Reports First Quarter 2016 Financial Results
PR Newswire - Wed May 04, 3:05PM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its first quarter 2016 financial results and ongoing progress with its pipeline, including duvelisib, an investigational, oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, and IPI-549, an immuno-oncology development candidate that selectively inhibits PI3K-gamma.
INFI: 4.81 (-0.23)
Infinity to Participate in Three May Investor Conferences
PR Newswire - Wed Apr 27, 7:00AM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that management will be participating at the following investor conferences:
DB: 15.74 (-0.97), INFI: 4.81 (-0.23)
Infinity Announces the Date of its First Quarter 2016 Financial Results Conference Call and Webcast
PR Newswire - Wed Apr 20, 7:00AM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Wednesday, May 4, 2016, at 4:30 p.m. ET. During the call, management will review the company's first quarter 2016 financial results and provide an update on Infinity's business.
INFI: 4.81 (-0.23)
IPI-549 Alters the Immune-Suppressive Microenvironment and Enhances the Activity of Checkpoint Inhibitors in Preclinical Models
PR Newswire - Mon Apr 18, 7:00AM CDT
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced new preclinical data for IPI-549, an orally administered immuno-oncology development candidate that selectively inhibits phosphoinositide-3-kinase gamma (PI3K-gamma). Preclinical data in multiple solid tumor models demonstrate that IPI-549 targets immune cells and alters the immune-suppressive microenvironment, promoting an anti-tumor immune response that leads to tumor growth inhibition. Data also demonstrate that IPI-549 enhances the effects of checkpoint inhibitors, resulting in improved survival in murine models. These data were presented at the American Association for Cancer Research (AACR) Annual Meeting 2016 in New Orleans, Louisiana. A Phase 1 clinical study is under way to explore the safety and activity of IPI-549 both as a monotherapy and in combination with anti-PD-1 antibody therapy, a type of checkpoint inhibitor.
INFI: 4.81 (-0.23)
Downgrade Alert for Infinity Pharmaceuticals (INFI)
Comtex SmarTrend(R) - Wed Mar 23, 3:29AM CDT
Infinity Pharmaceuticals (NASDAQ:INFI) was downgraded from Neutral to Underperform at Wedbush today. The stock closed yesterday at $5.62 on volume of 1.7 million shares, above average daily volume of 665,000. Over the past year, Infinity Pharmaceuticals has traded in a range of $5.17 to $50.51 and closed yesterday at $5.62, 9% above that low. Over the last five market days, the 200-day moving average (MA) has gone down 1.1% while the 50-day MA has declined 0.5%.
INFI: 4.81 (-0.23)
Downtrend Call Working As Infinity Pharmaceuticals Stock Falls 23.1% (INFI)
Comtex SmarTrend(R) - Fri Mar 04, 4:49PM CST
SmarTrend identified a Downtrend for Infinity Pharmaceuticals (NASDAQ:INFI) on November 11th, 2015 at $8.79. In approximately 4 months, Infinity Pharmaceuticals has returned 23.05% as of today's recent price of $6.76.
INFI: 4.81 (-0.23)
Infinity Pharmaceuticals Down 25.8% Since SmarTrend Downtrend Call (INFI)
Comtex SmarTrend(R) - Fri Mar 04, 1:30PM CST
SmarTrend identified a Downtrend for Infinity Pharmaceuticals (NASDAQ:INFI) on November 11th, 2015 at $8.79. In approximately 4 months, Infinity Pharmaceuticals has returned 25.78% as of today's recent price of $6.52.
INFI: 4.81 (-0.23)
Shares of INFI Down 33.0% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Fri Feb 19, 9:32AM CST
SmarTrend identified a Downtrend for Infinity Pharmaceuticals (NASDAQ:INFI) on November 11th, 2015 at $8.79. In approximately 3 months, Infinity Pharmaceuticals has returned 32.95% as of today's recent price of $5.89.
INFI: 4.81 (-0.23)
Can DENTSPLY (XRAY) Pull a Surprise this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Feb 10, 12:45PM CST
DENTSPLY International, Inc. (XRAY) is set to report fourth-quarter 2015 earnings results on Feb 12.
AHS: 39.97 (-1.01), INFI: 4.81 (-0.23), XRAY: 63.61 (-0.82), MGLN: 66.77 (-0.65)
NCCN Awarded $2 Million in Research Funding From Infinity Pharmaceuticals to Study Duvelisib in Hematologic Malignancies
Marketwired - Tue Feb 09, 8:05AM CST
The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has been awarded a $2-million grant from Infinity Pharmaceuticals, Inc. to evaluate the safety and effectiveness of duvelisib as a potential treatment for hematologic malignancies.
INFI: 4.81 (-0.23)
Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015
M2 - Fri Feb 05, 10:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/rfgg5w/relapsed_chronic) has announced the addition of the "Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Chronic Lymphocytic Leukemia (CLL) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Relapsed Chronic Lymphocytic Leukemia (CLL) Overview - Therapeutics Development - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Overview - Pipeline Products for Relapsed Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies - Relapsed Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes - Relapsed Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development - 4SC AG - AbbVie Inc. - Astellas Pharma Inc. - Astex Pharmaceuticals, Inc. - AstraZeneca Plc - Boehringer Ingelheim GmbH - Bristol-Myers Squibb Company - Celgene Corporation - Cyclacel Pharmaceuticals, Inc. - Emergent BioSolutions Inc. - F. Hoffmann-La Roche Ltd. - Gilead Sciences, Inc. - Hutchison MediPharma Limited - ImmunoGen, Inc. - Immunomedics, Inc. - Incyte Corporation - Infinity Pharmaceuticals, Inc. - Innate Pharma SA - Juno Therapeutics Inc. - Karyopharm Therapeutics, Inc. - Les Laboratoires Servier SAS - LFB S.A. - Lymphocyte Activation Technologies, S.A. - MedImmune, LLC - Millennium Pharmaceuticals, Inc. - MorphoSys AG - Novartis AG - Ono Pharmaceutical Co., Ltd. - Portola Pharmaceuticals, Inc. - Sanofi - TG Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Tragara Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/rf...ed_chronic
CYCC: 5.95 (-0.14), ABBV: 61.00 (+0.25), INFI: 4.81 (-0.23), JUNO: 42.98 (-2.55), IMMU: 3.05 (-0.08), PTLA: 26.38 (-0.46), EBS: 42.30 (-1.19), INCY: 80.41 (-1.20), IMGN: 4.96 (-0.11), TGTX: 7.16 (-0.23), BMY: 72.65 (-0.08), GILD: 84.45 (-1.32), AZN: 27.97 (-0.99), CELGZ: 1.46 (-0.04), KPTI: 8.53 (-0.60), NVS: 78.94 (-1.57)
Commit To Buy Infinity Pharmaceuticals At $5, Earn 22.4% Annualized Using Options
StockOptionsChannel.com - Wed Feb 03, 10:52AM CST
Investors eyeing a purchase of Infinity Pharmaceuticals Inc stock, but cautious about paying the going market price of $5.80/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
INFI: 4.81 (-0.23)
